MX371108B - Pirimidopirimidinonas utiles como iniciadores de wee-1 cinasa. - Google Patents

Pirimidopirimidinonas utiles como iniciadores de wee-1 cinasa.

Info

Publication number
MX371108B
MX371108B MX2016007801A MX2016007801A MX371108B MX 371108 B MX371108 B MX 371108B MX 2016007801 A MX2016007801 A MX 2016007801A MX 2016007801 A MX2016007801 A MX 2016007801A MX 371108 B MX371108 B MX 371108B
Authority
MX
Mexico
Prior art keywords
wee
useful
pyrimidopyrimidinones
kinase inhibitors
compounds
Prior art date
Application number
MX2016007801A
Other languages
English (en)
Other versions
MX2016007801A (es
Inventor
Harrison Timothy
Trevitt Graham
Roderick O´Dowd Colin
John Wilkinson Andrew
robin hewitt Peter
Burkamp Frank
d shepherd Steven
Miel Hugues
Original Assignee
Almac Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almac Discovery Ltd filed Critical Almac Discovery Ltd
Publication of MX2016007801A publication Critical patent/MX2016007801A/es
Publication of MX371108B publication Critical patent/MX371108B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La presente invención se relaciona con compuestos que son útiles como inhibidores de la actividad de Wee-1 cinasa. La presente invención también se relaciona con composiciones farmacéuticas que comprenden estos compuestos y con métodos para utilizar estos compuestos en el tratamiento de cáncer y métodos para tratar cáncer.
MX2016007801A 2013-12-19 2014-12-19 Pirimidopirimidinonas utiles como iniciadores de wee-1 cinasa. MX371108B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1322602.2A GB201322602D0 (en) 2013-12-19 2013-12-19 Pharmaceutical compounds
PCT/GB2014/053793 WO2015092431A1 (en) 2013-12-19 2014-12-19 Pyrimidopyrimidinones useful as wee-1 kinase inhibitors

Publications (2)

Publication Number Publication Date
MX2016007801A MX2016007801A (es) 2016-09-07
MX371108B true MX371108B (es) 2020-01-17

Family

ID=50071157

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016007801A MX371108B (es) 2013-12-19 2014-12-19 Pirimidopirimidinonas utiles como iniciadores de wee-1 cinasa.

Country Status (27)

Country Link
US (1) US9850247B2 (es)
EP (1) EP3083625B1 (es)
JP (1) JP6437559B2 (es)
KR (1) KR102405462B1 (es)
CN (1) CN105829315B (es)
AU (1) AU2014369457B2 (es)
BR (1) BR112016014151B1 (es)
CA (1) CA2933755C (es)
CY (1) CY1120035T1 (es)
DK (1) DK3083625T3 (es)
ES (1) ES2650013T3 (es)
GB (1) GB201322602D0 (es)
HR (1) HRP20180080T1 (es)
HU (1) HUE037908T2 (es)
IL (1) IL245672B (es)
LT (1) LT3083625T (es)
MX (1) MX371108B (es)
NO (1) NO3083625T3 (es)
NZ (1) NZ720178A (es)
PL (1) PL3083625T3 (es)
PT (1) PT3083625T (es)
RS (1) RS56731B1 (es)
RU (1) RU2691105C1 (es)
SG (1) SG11201603814TA (es)
SI (1) SI3083625T1 (es)
WO (1) WO2015092431A1 (es)
ZA (1) ZA201603337B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016168992A1 (en) * 2015-04-21 2016-10-27 Ruijin Hospital Affiliated To Shanghai Jiao Tong University School Of Medicine Preparation and use of novel protein kinase inhibitors
WO2017075629A2 (en) * 2015-11-01 2017-05-04 The Regents Of The University Of Colorado, A Body Corporate Wee 1 kinase inhibitors and methods of making and using the same
CN109906227B (zh) * 2016-11-16 2022-03-11 上海瑛派药业有限公司 8,9-二氢咪唑[1,2-a]嘧啶并[5,4-e]嘧啶-5(6H)-酮类化合物
CA3048376A1 (en) 2016-12-27 2018-07-05 Riken Bmp-signal-inhibiting compound
WO2018133829A1 (zh) * 2017-01-23 2018-07-26 南京明德新药研发股份有限公司 作为Wee1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮衍生物
GB201703881D0 (en) * 2017-03-10 2017-04-26 Almac Discovery Ltd Pharmaceutical compounds
AU2018243667A1 (en) 2017-03-31 2019-10-17 Seagen Inc. Combinations of Chk1- and Wee1 - inhibitors
CN110914277B (zh) * 2017-07-10 2022-08-09 上海瑛派药业有限公司 咪唑并[1,2-b]嘧啶并[4,5-d]哒嗪-5(6H)-酮类化合物及其应用
CN109422754A (zh) * 2017-08-24 2019-03-05 上海迪诺医药科技有限公司 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
US11299493B2 (en) 2017-10-09 2022-04-12 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
AU2018347307A1 (en) 2017-10-09 2020-04-23 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
BR112020008664A8 (pt) 2017-11-01 2023-01-17 Shijiazhuang Sagacity New Drug Dev Co Ltd Composto macrocíclico que atua como inibidor de weel e aplicações do mesmo
US20200405723A1 (en) * 2018-02-28 2020-12-31 The Regents Of The University Of Colorado, A Body Corporate Wee1 kinase inhibitors and methods of treating cancer using the same
MX2021003531A (es) 2018-09-27 2021-07-21 Betta Pharmaceuticals Co Ltd Inhibidor de fgfr4 y su uso.
CN112955454A (zh) 2018-10-26 2021-06-11 石家庄智康弘仁新药开发有限公司 作为Wee1抑制剂的嘧啶并吡唑酮类衍生物及其应用
CN113614087B (zh) 2019-03-22 2023-06-02 首药控股(北京)股份有限公司 Wee1抑制剂及其制备和用途
EP3952878A4 (en) * 2019-04-09 2023-01-04 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AND USES THEREOF
EP3952879A4 (en) * 2019-04-09 2023-01-04 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AND USES THEREOF
JP2022526831A (ja) 2019-04-09 2022-05-26 ニューベイション・バイオ・インコーポレイテッド ヘテロ環式化合物およびその使用
EP3964510A4 (en) 2019-04-30 2023-04-26 Wuxi Biocity Biopharmaceutics Co., Ltd. WEE1 INHIBITOR COMPOUND CRYSTAL FORM AND USE
CN112142763B (zh) * 2019-06-28 2024-01-26 上海医药集团股份有限公司 一种吡唑酮并嘧啶类化合物、其制备方法及应用
EP4169919A1 (en) 2020-06-17 2023-04-26 Wigen Biomedicine Technology (Shanghai) Co., Ltd. Pyrazolo[3,4-d]pyrimidine-3-ketone derivative as wee-1 inhibitor
US20230416247A1 (en) * 2020-10-01 2023-12-28 University Of Washington Drug-like molecules and methods for the therapeutic targeting of microrna-21
CA3201152A1 (en) * 2020-12-18 2022-06-23 Xiaoyang Dong Nitrogen containing 2,3-dihydroquinazolinone compounds as nav1.8 inhibitors
JP2024515318A (ja) 2021-04-30 2024-04-08 ウィゲン・バイオメディシン・テクノロジー・（シャンハイ）・カンパニー・リミテッド Ｗｅｅ－１阻害剤としての縮合環状化合物、その調製方法およびその使用
CN116836184A (zh) * 2022-03-25 2023-10-03 药雅科技(上海)有限公司 Wee1激酶抑制剂的制备及其应用
WO2023217201A2 (zh) * 2022-05-10 2023-11-16 杭州德睿智药科技有限公司 作为Wee1抑制剂的新型嘧啶并杂环类新化合物及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7504396B2 (en) 2003-06-24 2009-03-17 Amgen Inc. Substituted heterocyclic compounds and methods of use
EP1727819A1 (en) 2004-03-15 2006-12-06 F.Hoffmann-La Roche Ag Novel dichloro-phenyl-pyrido¬2,3-d|pyrimidine derivatives, their manufacture and use as pharmaceutical agents
FR2896246B1 (fr) 2006-01-13 2008-08-15 Sanofi Aventis Sa Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.
PE20080695A1 (es) 2006-04-27 2008-06-28 Banyu Pharma Co Ltd Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel
EP2155752B1 (en) 2007-04-25 2018-09-19 Merck Sharp & Dohme Corp. Polymorph of dihydropyrazolopyrimidinone derivative as weel kinase.inhibitor
CA2689429C (en) 2007-06-15 2012-08-21 Banyu Pharmaceutical Co., Ltd. Bicycloaniline derivatives
WO2009054332A1 (ja) * 2007-10-23 2009-04-30 Banyu Pharmaceutical Co., Ltd. ピリドン置換ジヒドロピラゾロピリミジノン誘導体
WO2010067886A1 (en) 2008-12-12 2010-06-17 Banyu Pharmaceutical Co.,Ltd. Dihydropyrimidopyrimidine derivative
CA2745959A1 (en) * 2008-12-12 2010-06-17 Msd K.K. Dihydropyrimidopyrimidine derivatives
EP2649053B1 (en) * 2010-12-06 2015-11-04 Glaxo Group Limited Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by lp-pla2
WO2012085167A1 (en) * 2010-12-22 2012-06-28 Merz Pharma Gmbh & Co. Kgaa Metabotropic glutamate receptor modulators
TWI532742B (zh) * 2011-02-28 2016-05-11 艾伯維有限公司 激酶之三環抑制劑
EP2731953A1 (en) 2011-07-15 2014-05-21 Abbvie Inc. Tricyclic inhibitors of kinases useful for the treatment of proliferative diseases
WO2013013031A1 (en) * 2011-07-19 2013-01-24 Abbvie Inc. Pyridazino [4, 5 -d] pyrimidin- (6h) -one inhibitors of wee - 1 kinase
JP2014530867A (ja) * 2011-10-20 2014-11-20 アッヴィ・インコーポレイテッド キナーゼのピリドピリミジノン阻害剤
CN104271576A (zh) 2012-02-23 2015-01-07 艾伯维公司 激酶的吡啶并嘧啶酮抑制剂
CN102816164A (zh) * 2012-08-31 2012-12-12 北京理工大学 一种合成7-氨基-2,3-二氢嘧啶[4,5-d]嘧啶-4(1H)-酮的方法

Also Published As

Publication number Publication date
BR112016014151B1 (pt) 2023-01-17
SI3083625T1 (en) 2018-03-30
KR20160098499A (ko) 2016-08-18
NO3083625T3 (es) 2018-03-31
MX2016007801A (es) 2016-09-07
AU2014369457B2 (en) 2018-08-09
BR112016014151A2 (es) 2017-08-08
EP3083625A1 (en) 2016-10-26
RU2691105C1 (ru) 2019-06-11
GB201322602D0 (en) 2014-02-05
KR102405462B1 (ko) 2022-06-03
ES2650013T3 (es) 2018-01-16
HUE037908T2 (hu) 2018-09-28
SG11201603814TA (en) 2016-07-28
PL3083625T3 (pl) 2018-03-30
IL245672A0 (en) 2016-06-30
RU2016123363A (ru) 2018-01-25
US20160318936A1 (en) 2016-11-03
NZ720178A (en) 2022-05-27
CA2933755C (en) 2023-01-31
CA2933755A1 (en) 2015-06-25
JP6437559B2 (ja) 2018-12-12
WO2015092431A1 (en) 2015-06-25
HRP20180080T1 (hr) 2018-03-09
PT3083625T (pt) 2018-02-06
JP2017500335A (ja) 2017-01-05
IL245672B (en) 2021-10-31
US9850247B2 (en) 2017-12-26
ZA201603337B (en) 2018-07-25
EP3083625B1 (en) 2017-11-01
CY1120035T1 (el) 2018-12-12
AU2014369457A1 (en) 2016-06-09
RS56731B1 (sr) 2018-03-30
DK3083625T3 (en) 2017-12-18
CN105829315B (zh) 2019-03-08
LT3083625T (lt) 2017-12-27
CN105829315A (zh) 2016-08-03

Similar Documents

Publication Publication Date Title
MX371108B (es) Pirimidopirimidinonas utiles como iniciadores de wee-1 cinasa.
PH12019502810A1 (en) Bicyclic heterocycles as fgfr inhibitors
PH12019502809A1 (en) Substituted tricyclic compounds as fgfr inhibitors
MX2018008052A (es) Inhibidores de desmetilasa especifica de lisina 1 (lsd1).
PH12017501483A1 (en) Bicyclic heterocycles as fgfr4 inhibitors
MX362215B (es) Derivados 2-aminopirido-[4,3-d]pirimidin-5-ona y su uso como inhibidores de wee-1.
PH12016500330B1 (en) Certain chemical entities, compositions, and methods
PH12016501139B1 (en) Bicyclic heterocycle compounds and their uses in therapy
MX2020010535A (es) Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
MX2015006478A (es) Inhibidores de glutaminasa y metodos de empleo.
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
MX2015012502A (es) Inhibidores de proteina cinasa dependiente de adn.
EA201590987A1 (ru) Соединения и способы их применения
MX359418B (es) Pteridinas como inhibidores del receptor del factor de crecimiento de fribroblasto (fgfr).
EA201691032A1 (ru) Производные изохромена в качестве ингибиторов фосфоинозитид-3-киназ
EA201692483A1 (ru) Ингибиторы гистоновой метилазы
MX2019013808A (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer.
EA201692313A1 (ru) Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ
MX2017006015A (es) Composiciones para usar en el tratamiento de cancer renal.
MY195580A (en) Pyrimidopyrimidinones Useful as Wee-1 Kinase Inhibitors
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
MX2016006975A (es) Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias.
MX2017006026A (es) Apilimod para uso en el tratamiento de cancer colorrectal.
EA201791933A1 (ru) Ингибирование активности olig2
EA201690376A1 (ru) Ингибиторы дезоксицитидинкиназы

Legal Events

Date Code Title Description
FG Grant or registration